Cas:217645-70-0 BX471 manufacturer & supplier

Chemical Name:BX471

CAS.NO:217645-70-0

Synonyms:BX471;1-(5-chloro-2-{2-[(2R)-4-(4-fluorobenzyl)-2-methylpiperazin-1-yl]-2-oxoethoxy}phenyl)urea;BX-471 free base;1-(5-Chloro-2-{2-[(2R)-4-(4-fluorobenzyl)-2-methyl-1-piperazinyl]-2-oxoethoxy}phenyl)urea;Urea, N-[5-chloro-2-[2-[(2R)-4-[(4-fluorophenyl)methyl]-2-methyl-1-piperazinyl]-2-oxoethoxy]phenyl]-;UNII-76K17ZG4ZN;ZK 811752;BX-471;ZK-811752

Molecular Formula:C₂₁H₂₄ClFN₄O₃

Molecular Weight:434.892

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:593.5±50.0 °C at 760 mmHg

Density:1.3±0.1 g/cm3

Index of Refraction:1.617

PSA:88.89000

Exact Mass:434.152100

LogP:2.77

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like BX471 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,ZK-811752 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,UNII-76K17ZG4ZN Use and application,ZK 811752 technical grade,usp/ep/jp grade.

Related News: Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access. BX471 manufacturer That impacts airlines’ business, making it less financially attractive for them to fly those routes to China. BX471 supplier That impacts airlines’ business, making it less financially attractive for them to fly those routes to China. BX471 vendor Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access. BX471 factory However, the study did not produce any significant benefits when it came to thinking, reasoning and memory tests performed across the entire patient group — possibly because there were too few people with clinically diagnosed Alzheimer’s participating in the trial.